title: Systemic sclerosis: establishing diagnostic criteria.
abstract: We designed the current study to describe the spectrum of disease expression in systemic sclerosis (SSc) in a large cohort and to develop diagnostic criteria for SSc. We assessed patients in the Canadian Scleroderma Research Group Registry by standardized history, physical examination, and laboratory testing. We performed regression tree analysis to determine the sensitivity of various clinical and serologic features for diagnosing SSc. Over 1000 (n = 1048) patients were included: mean age 55 (+/- 12) years, 87% female, 90% white, mean disease duration 11 (+/- 10) years, and 38% with diffuse skin involvement. Common clinical features were Raynaud phenomenon (98%), sclerodactyly (92%), clinically visible mat-like telangiectasias (78%), skin involvement above the fingers (58%), lung fibrosis (35%), pulmonary hypertension (15%), and gastrointestinal tract involvement (mean number of self-reported symptoms, 4 (+/- 3) out of a possible 14). Almost 90% of patients had at least 1 SSc-related autoantibody, including 34% with anti-centromere and 16% with anti-topoisomerase I. The sensitivity of Raynaud and proximal finger skin thickening for the diagnosis of SSc was only 57%. Addition of clinically visible mat-like telangiectasias and SSc-related antibodies improved the sensitivity to 97%. We conclude that important diagnostic clues in patients with SSc include Raynaud phenomenon, skin involvement, clinically visible mat-like telangiectasias, and SSc-related autoantibodies.
authors.affiliation: From Jewish General Hospital and McGill University (MH, MB), Montreal, Quebec; and University of Calgary (MJF), Calgary, Alberta, Canada.
authors.forename: Marie
authors.initials: M
authors.lastname: Hudson
authors.forename: Marvin J
authors.initials: MJ
authors.lastname: Fritzler
authors.forename: Murray
authors.initials: M
authors.lastname: Baron
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood; D002170:Canada; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011928:Raynaud Disease / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications* / Q000175:diagnosis* / Q000276:immunology; D012871:Skin Diseases / Q000209:etiology; D013684:Telangiectasis / Q000209:etiology
chemical_list: D001323:Autoantibodies
references.citation: Ashida R, Ihn H, Mimura Y, Jinnin M, Asano Y, Kubo M, Tamaki K. Clinical features of scleroderma patients with contracture of phalanges. Clin Rheumatol. 2007;26:1275-1277.
references.citation: Baron M, Lee P, Keystone EC. The articular manifestations of progressive systemic sclerosis (scleroderma). Ann Rheum Dis. 1982;41:147-152.
references.citation: Bernatsky S, Hudson M, Panopalis P, Clarke A, Pope J, LeClercq S, St Pierre Y, Baron M, Canadian Scleroderma Research Group. The cost of systemic sclerosis. Arthritis Rheum. 2008;61:119-123.
references.citation: Block J, Sequeira W. Raynaud's phenomenon. Lancet. 2001;357:2042-2048.
references.citation: Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet. 2006;367:1683-1691.
references.citation: Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223-235.
references.citation: Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281-1285.
references.citation: Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137-145.
references.citation: Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum. 2007;57:429-439.
references.citation: Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620-628.
references.citation: LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
references.citation: LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-1576.
references.citation: Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, Choquette D, Raymond Y, Senecal JL. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 2001;44:735-736.
references.citation: Matucci-Cerinic M, Allanore Y, Czirjak L, Tyndall A, Muller-Ladner U, Denton C, Valentini G, Distler O, Fligelstone K, Tyrrel-Kennedy A, Farge D, Kowal-Bielecka O, van den Hoogen F, Cutolo M, Sampaio-Barros PD, Nash P, Takehara K, Furst DE. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009;68:1377-1380.
references.citation: Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246-2255.
references.citation: Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26:2159-2167.
references.citation: Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
references.citation: Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol. 2008;22:339-350.
references.citation: Robert-Thomson PJ, Mould TL, Walker JG, Smith MD, Ahern MJ. Clinical utility of telangiectasia of hands in scleroderma and other rheumatic disorders. Asian Pac J Allergy Immunol. 2002;20:7-12.
references.citation: Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29:315-333.
references.citation: Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-944.
references.citation: Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-2444.
references.citation: Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40:1984-1991.
references.citation: Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-590.
references.citation: Valentini G, Black C. Systemic sclerosis. Best Pract Res Clin Rheumatol. 2002;16:807-816.
references.citation: van Gestel A, Haagsma C, van Riel P. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845-1850.
references.citation: Ware JE Jr, Sherbourne CD. The MOS 36 item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.